GlycanLink

GlycanLink Biopharmaceuticals Co., Ltd., located in Shanghai Zhangjiang Med Valley, is a biopharmaceutical company specializing in ADC site-specific conjugation technology. Founded in 2021 by researcher Wei Huang from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, GlycanLink currently holds multiple proprietary ADC site-specific conjugation technologies with independent intellectual property rights. GlycanLink is committed to building a world-class site-specific ADC technology platform both domestically and internationally, leveraging innovation-driven transformation to help clients develop ADC drugs with simpler processes, more significant efficacy, and higher safety through collaboration and licensing dual models. Meanwhile, GlycanLink actively advances its self-developed pipeline, promoting multi-pipeline research on various potential ADC targets, including popular and emerging targets, with the goal of achieving the first ADC product's IND filing within two years.